Altered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort

BJU International

Volumn 116, Issue 2, 2015, Pages 207-212

  Bolton, Damien ^a,b   Cheng, Yuan ^a,b   Willems Jones, Amber J ^a   Li, Jason ^a   Niedermeyr, Eveline ^a   Mitchell, Gillian ^a   Clouston, David ^c   Lawrentschuk, Nathan ^b   Sliwinski, Ania ^a,b   Fox, Stephen ^a   Thorne, Heather ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Tissupath Pty Ltd   (Australia)

Author keywords

BRCA2; D'Amico risk classification; familial cancer history; prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; D' AMICO RISK CLASSIFICATION; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETICS; PROSTATIC NEOPLASMS;

BRCA2 PROTEIN;

AGED; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84937519133     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12792     Document Type: Article

References (16)

1. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-6
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92
3. Liede A, Karlan BY, Narod SA,. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22: 735-42
4. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-8
5. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997; 61: 120-8
6. Thorne H, Willems AJ, Niedermayr E, et al. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 2011; 4: 1002-10
7. Sigurdsson S, Thorlacius S, Tomasson J, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997; 75: 758-61
8. Narod SA, Neuhausen S, Vichodez G, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99: 371-4
9. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-21
10. Edwards SM, Evans DG, Hope Q, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010; 103: 918-24
11. Mohler JL,. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 2010; 8: 145
12. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML,. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179: 1354-61
13. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
14. Mann GJ, Thorne H, Balleine RL, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006; 8: R12
15. Cooperberg MR, Cowan J, Broering JM, Carroll PR,. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008; 26: 211-8
16. Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E,. Survival in prostate carcinoma-outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 2005; 103: 943-51